1. Home
  2. ASTH vs TYRA Comparison

ASTH vs TYRA Comparison

Compare ASTH & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Astrana Health Inc.

ASTH

Astrana Health Inc.

HOLD

Current Price

$23.86

Market Cap

1.2B

ML Signal

HOLD

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$37.52

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASTH
TYRA
Founded
1994
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
ASTH
TYRA
Price
$23.86
$37.52
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
9
Target Price
$34.00
$44.63
AVG Volume (30 Days)
479.2K
1.2M
Earning Date
03-02-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.46
N/A
Revenue
$519,907,752.00
N/A
Revenue This Year
$27.32
N/A
Revenue Next Year
$10.84
N/A
P/E Ratio
$52.61
N/A
Revenue Growth
45.90
N/A
52 Week Low
$18.08
$6.42
52 Week High
$34.80
$38.56

Technical Indicators

Market Signals
Indicator
ASTH
TYRA
Relative Strength Index (RSI) 53.05 67.37
Support Level $23.14 $30.10
Resistance Level $27.01 N/A
Average True Range (ATR) 1.35 2.30
MACD 0.06 0.19
Stochastic Oscillator 31.14 86.52

Price Performance

Historical Comparison
ASTH
TYRA

About ASTH Astrana Health Inc.

Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: